曲美他嗪治疗慢性充血性心力衰竭临床疗效及安全性分析

Analysis of Clinical Curative Effect and Safety of Trimetazidine in Treatment of Chronic congestive Heart Failure

目的探讨曲美他嗪治疗慢性充血性心力衰竭临床疗效,同时分析其安全性。方法方便选取2015年6月—2016年12月于该院就诊并选择曲美他嗪进行治疗的慢性充血性心力衰竭患者86例作为观察组,同时选取同期于该院进行常规药物治疗的慢性充血性心力衰竭患者86例作为对照组。将两组患者的临床疗效、左心室收缩、舒张末期内径及射血分数和不良反应发生情况进行对比。结果观察组(94.2%)患者治疗效果显著优于对照组(79.1%)(P<0.05);两组患者治疗前的左心室收缩、舒张末期内径及射血分数差异无统计学意义(P>0.05),治疗后观察组的左心室收缩、舒张末期内径分别为(41.3±3.3)、(57.6±5.8)mm,均显著小于对照组的(52.5±4.2)、(65.0±6.2)mm,差异有统计学意义(P<0.05),左心室射血分数为(47.1±4.5)%,显著高于对照组(40.5±3.8)%,差异有统计学意义(P<0.05)。在治疗过程中,观察组出现不良反应2例,对照组出现3例,不良反应发生情况差异无统计学意义(P>0.05);治疗前后肝肾功能、血常规情况均无显著变化(P>0.05)。结论曲美他嗪治疗慢性充血性心力衰竭临床疗效显著,可改善患者心肌功能,同时安全性较高。

Objective To discuss the clinical curative effect and safety of trimetazidine in treatment of chronic congestive heart failure. Methods 86 cases of patients with chronic congestive heart failure treated with trimetazidine diagnosed in our hospital from June 2015 to December 2016 were convenient selected as the observation group, while 86 cases of patients with chronic congestive heart failure treated with routine drugs in our hospital were selected as the control group, and the clinical curative effect, left ventricular systolic index, end-diastolic diameter, ejection fraction and occurrence of adverse reactions were compared between the two groups. Results The treatment effect in the observation group was obviously better than that in the control group(94.2% vs 79.1%)(P<0.05), and there were no obvious differences in the left ventricular systolic index, end-diastolic diameter, ejection fraction and occurrence of adverse reactions between the two groups before treatment(P>0.05), after treatment, the left ventricular systolic index and end-diastolic diameter in the observation group were obviously fewer than those in the control group [(41.3±3.3)、(57.6±5.8)mm vs(52.5±4.2)、(65.0±6.2)mm],the difference was statistically signifieant(P<0.05), and the left ventricular ejection fraction was obviously higher than that in the control group(47.1±4.5)% vs(40.5 ±3.8)%], with statistical significance(P<0.05).In the process of the treatment,there were 2 Adverse reactions In the observation group,and 3 in The control group,and the difference between the two groups had no statistical significance(P>0.05);the liver function renal function and the blood routine examination no obvious change before and after treatment(P>0.05). Conclusion The clinical curative effect of trimetazidine in treatment of chronic congestive heart failure can improve the myocardial function and the safety is higher.